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Background: Due to the lack of protective immunity of humans towards the newly emerged SARS-CoV-2, this
virus has caused a massive pandemic across the world resulting in hundreds of thousands of deaths. Thus, a
vaccine is urgently needed to contain the spread of the virus.
Methods: Here, we describe Newcastle disease virus (NDV) vector vaccines expressing the spike protein of
SARS-CoV-2 in its wild type format or a membrane-anchored format lacking the polybasic cleavage site. All
described NDV vector vaccines grow to high titers in embryonated chicken eggs. In a proof of principle mouse
study, the immunogenicity and protective efficacy of these NDV-based vaccines were investigated.
Findings: We report that the NDV vector vaccines elicit high levels of antibodies that are neutralizing when
the vaccine is given intramuscularly in mice. Importantly, these COVID-19 vaccine candidates protect mice
from a mouse-adapted SARS-CoV-2 challenge with no detectable viral titer and viral antigen in the lungs.
Interpretation: The results suggested that the NDV vector expressing either the wild type S or membrane-
anchored S without the polybasic cleavage site could be used as live vector vaccine against SARS-CoV-2.
Funding: This work is supported by an NIAID funded Center of Excellence for Influenza Research and Surveil-
lance (CEIRS) contract, the Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract, philanthropic
donations and NIH grants.
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The unprecedented coronavirus disease 2019 (COVID-19) pan-
demic caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has resulted in ~16.3 million infections with more than
half a million deaths since the end of 2019 as of July 26th 2020, and
continues to pose a threat to public health. To mitigate the spread of
the virus, social distancing, mask-wearing, and the lockdown of cities,
states or even countries were practiced, with a heavy price paid both
medically and economically. Unfortunately, due to the relative lack of
pre-existing immunity of humans to this virus, no countermeasures
will be completely effective without a vaccine. Because of the urgentneed for an effective SARS-CoV-2 vaccine, many candidates are being
developed using various vaccine platforms, including mRNA vaccines
[1,2], inactivated whole virus vaccines [3], subunit vaccines, DNA vac-
cines and viral vector vaccines [4]. These vaccine candidates are
designed to essentially target the spike (S) protein of the SARS-CoV-2
[5], which is the major structural protein displayed on the surface of
the SARS-CoV-2. The S protein mediates the entry of the virus via
binding to the angiotensin converting enzyme 2 (ACE2) receptor in
humans. The S protein is also the most important antigen of the virus
that harbors many B cell and T cell epitopes [6-9]. Neutralizing anti-
bodies, most of which target the receptor-binding domain (RBD), can
be induced by the S protein [9,10]. However, to eventually contain
the virus spread worldwide, not only the efficacy, but also the cost
and scalability of the vaccine are crucial, especially in low and middle
income countries with limited resources.
Research in context
Evidence before this study
The spike (S) protein of the SARS-CoV-2 is the major antigen
that notably induces neutralizing antibodies to block viral
entry. Many COVID-19 vaccines are under development, among
them viral vectors expressing the S protein of SARS-CoV-2
exhibit many benefits. Viral vector vaccines have the potential
of being used as both live or inactivated vaccines and they can
induce Th1 and Th2-based immune responses following differ-
ent immunization regimens. Additionally, viral vector vaccines
can be handled under BSL-2 conditions and they grow to high
titers in cell cultures or other species restricted-hosts. For a
SARS-CoV-2 vaccine, several viral vectors are being tested, such
as adenovirus, measles virus and Modified vaccinia Ankara.
Added value of this study
The NDV vector vaccine against SARS-CoV-2 described in this
study has advantages similar to those of other viral vector vac-
cines. But the NDV vector can be amplified in embryonated
chicken eggs, which allows for high yields and low costs per
dose. Also, the NDV vector is not a human pathogen, therefore
the delivery of the foreign antigen would not be compromised
by any pre-existing immunity in humans. Finally, NDV has a
very good safety record in humans, as it has been used in many
oncolytic virus trials. This study provides an important option
for a cost-effective SARS-CoV-2 vaccine.
Implications of all the available evidence
This study informs of the value of a viral vector vaccine against
SARS-CoV-2. Specifically, for this NDV based SARS-CoV-2 vac-
cine, the existing egg-based influenza virus vaccine manufac-
tures in the U.S. and worldwide would have the capacity to
rapidly produce hundreds of millions of doses to mitigate the
consequences of the ongoing COVID-19 pandemic.
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castle disease virus (NDV) vectors expressing the SARS-CoV-2 S
protein. NDV belongs to the genus of Avulavirus in the family of Par-
amyxoviridae, it is an avian pathogen, typically causing no symp-
toms in humans although mild influenza-like symptoms or
conjunctivitis have been described in rare cases. The lentogenic
NDV vaccine strain such as the LaSota strain, in addition to be aviru-
lent in birds, has been used as an oncolytic agent and a vaccine vec-
tor [11-15]. As a large negative strand RNA virus, NDV is stable and
well tolerates transgenes into its genome. NDV vectors have been
successfully used to express the spike protein of other coronavi-
ruses [16,17]. The NDV platform is also appealing, because the virus
grows to high titers in embryonated chicken eggs, which are also
used to produce influenza virus vaccines. Humans typically lack
pre-existing immunity toward the NDV, which makes the virus
preferable over other viral vectors that are human pathogens, such
as human adenovirus, measles virus or Modified Vaccinia Ankara
(MVA). The lentogenic NDV vector has proven to be safe in humans
as it has been tested extensively in human trials [18-20]. Most
importantly, at low cost, NDV vector vaccines could be generated in
embryonated chicken eggs quickly under biosafety level 2 (BSL-2)
conditions to meet the vast demand on a global scale. In this study,
we have successfully rescued NDV vectors expressing two forms of
the spike protein of SARS-CoV-2, the wild type (WT) S and a chime-
ric version containing the ectodomain (with the polybasic cleavage
site deleted) of the spike and the transmembrane domain andcytoplasmic domain of the NDV F (S-F chimera). We have shown
that WT S and S-F were well expressed from the NDV as transgenes
in infected cells. While both WT S and S-F were displayed on the
surface of the NDV particles, the incorporation of the S-F into NDV
particles was substantially improved compared to that of the WT S,
as expected. A proof of concept study in mice using three live NDV
vectors expressing the spike protein (NDV_LS_S, NDV_LS_S-F and
NDV_LS/L289A_S-F) showed that high titers of binding and neutral-
izing antibodies were induced. All three NDV vector vaccines fully
protected mice from challenge with a SARS-CoV-2 mouse-adapted
strain, showing no detectable viral titers and viral antigens in the
lungs at day four post-challenge. To conclude, we have developed
promising cost-effective SARS-CoV-2 vaccine candidates using the
NDV LaSota strain as the viral vector, which could be generated to
high yield under BSL-2 conditions.
2. Methods
2.1. Plasmids
The sequence of the wild type S was amplified from pCAGGS plas-
mid [21] encoding the codon-optimized nucleotide sequence of the
spike gene (GenBank: MN908947.3) of a SARS-CoV-2 isolate by PCR,
using primers containing the gene end (GE), gene start (GS) and a
Kozak sequences at the 50 end [22]. To construct the S-F chimera,
the ectodomain of the S without the polybasic cleavage site
(CS, 682RRAR685 to A) [22] was generated by PCR. A mammalian cell
codon-optimized nucleotide sequence of the transmembrane domain
(TM) and the cytoplasmic tail (CT) of the NDV LaSota fusion (F) pro-
tein was synthesized commercially (gBlock, Integrated DNA technol-
ogies). The S ectodomain (no CS) was fused to the TM/CT of F through
a GS linker (GGGGS). The sequence was again modified by adding GE,
GS and a Kozak sequence at the 50. Additional nucleotides were added
at the 30 of both inserts to follow the “rule of six”. The transgenes
were inserted between the P and M gene of the pNDV LaSota (LS)
wild type or the L289A [15,22,23] mutant (NDV_LS/L289A) antige-
nomic cDNA by in-Fusion cloning (Clontech). The recombination
products were transformed into NEB Stable Competent E. coli (NEB)
to generate NDV_LS_S, NDV_LS_S-F and NDV_LS/L289A_S-F rescue
plasmids. The plasmids were purified using QIAprep Spin Miniprep
kit (Qiagen) for Sanger sequencing (Macrogen). Maxipreps of rescue
plasmids were purified using PureLinkTM HiPure Plasmid Maxiprep
Kit (Thermo Fisher Scientific).
2.2. Cells
BSRT7 cells stably expressing the T7 polymerase were kindly pro-
vided by Dr. Benhur Lee at ISMMS. The cells were maintained in Dul-
becco’s Modified Eagle’s medium (DMEM; Gibco) containing 10%
(vol/vol) fetal bovine serum (FBS) and 100 unit/ml of penicillin/strep-
tomycin (P/S; Gibco) at 37 °C with 5% CO2. Vero E6 cells were
obtained from American Type Culture Collection (ATCC, CRL-1586).
Vero E6 cells were also maintained in DMEM containing 10% FBS
with 100 unit/ml P/S at 37 °C with 5% CO2.
2.3. Rescue of NDV LaSota expressing the spike protein of SARS-CoV-2
Six-well plates of BSRT7 cells were seeded 3 £ 105 cells per well
the day before transfection. The next day, a transfection cocktail
was prepared consisting of 250 ml of Opti-MEM (Gibco) including
4 mg of pNDV_LS_S or pNDV_LS_S-F or pNDV_LS/L289A_S-F, 2 mg
of pTM1-NP, 1 mg of pTM1-P, 1 mg of pTM1-L and 2 mg of pCI-
T7opt. Thirty ml of TransIT LT1 (Mirus) were added to the plasmid
cocktail and gently mixed by pipetting three times and incubated
at room temperature (RT) for 30 min. Toward the end of the incu-
bation, the medium was replaced with 1 ml of Opti-MEM. The
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plates were incubated at 37 °C with 5% CO2. Forty-eight hours post
transfection, the supernatant and the cells were harvested and
briefly homogenized by several strokes with an insulin syringe.
Two hundred microliters of the cell/supernatant mixture were
injected into the allantoic cavity of 8- to 10-day old specific patho-
gen free (SPF) embryonated chicken eggs. The eggs were incubated
at 37 °C for 3 days before being cooled at 4 °C overnight. The allan-
toic fluid was collected and clarified by low-spin centrifugation to
remove debris. The presence of the rescued NDV was determined
by hemagglutination (HA) assay using 0.5% chicken or turkey red
blood cells. The RNA of the positive samples was extracted and
treated with DNase I (Thermo Fisher Scientific). Reverse transcrip-
tase-polymerase chain reaction (RT-PCR) was performed to amplify
the transgenes. The sequences of the transgenes were confirmed
by Sanger Sequencing (Genewiz).2.4. Immunofluorescence assay (IFA)
Vero E6 cells were seeded onto 96-well tissue culture plates at
2.5 £ 104 cells per well. The next day, cells were washed with 100 ml
warm phosphate buffered saline (PBS) and infected with 50 ml of
allantoic fluid at 37 °C for 1 h. The inocula were removed and
replaced with 100 ml of growth medium. The plates were then incu-
bated at 37 °C. Sixteen to eighteen hours after infection, the cells
were washed with 100 ml of warm PBS and fixed with 4% methanol-
free paraformaldehyde (PFA) (Electron Microscopy Sciences) for
15 min at 4 °C. The PFA was discarded, cells were washed with PBS
and blocked in PBS containing 0.5% bovine serum albumin (BSA) for
1 hour at 4 °C. The blocking buffer was discarded and surface proteins
were stained with anti-NDV rabbit serum or SARS-CoV-2 spike recep-
tor-binding domain (RBD) specific human monoclonal antibody
CR3022 [24,25] for 2 h at RT. The primary antibodies were discarded,
cells were then washed 3 times with PBS and incubated with goat
anti-rabbit Alexa Fluor 488 or goat anti-human Alexa Fluor 488 sec-
ondary antibodies (Thermo Fisher Scientific) for 1 h at RT. The sec-
ondary antibodies were discarded, cells were washed again 3 times
with PBS and images were captured using an EVOS fl inverted fluo-
rescence microscope (AMG).2.5. Virus titration
Stocks of NDV expressing the S or S-F proteins were titered using
an immunofluorescence assay (IFA). Briefly, Vero cells were seeded
onto 96-well (Denville) tissue culture plates at 2.5 £ 104 cells/well
the day before infection. The next day, five-fold serial dilutions of
each virus stocks were prepared in a separate 96-well plate in Opti-
MEM (Gibco). Medium in the 96-well plate was removed and the
cells were washed with 100 mL of warm PBS. Fifty mL of the virus
dilutions were added to each well. The plates were incubated at 37 °C
for one hour and shaken every 15 min to ensure the cells were
infected evenly. The inoculum was removed and 100 mL of DMEM
containing 10% FBS with 100 unit/ml P/S was added. The plates were
incubated at 37 °C overnight for 16 to 18 h. The next day, the media
were aspirated off and cells were washed once with 100 mL of warm
PBS. IFA was performed as described above to staining NDV surface
glycoproteins. Infected fluorescent cells were counted starting from
the undiluted wells until a well down the dilution with a countable
number of cells was found. The fluorescent cells in the entire well
were counted. Titer of the virus (focus forming unit, FFU per ml) was
determined by the following formula:
Titer FFU=mlð Þ ¼ No:of fluorescent cells Dilution factor
 1000uL=volumeof infectionð Þ2.6. Virus concentration
Allantoic fluids were clarified by centrifugation at 4000 rpm using
a Sorvall Legend RT Plus Refrigerated Benchtop Centrifuge (Thermo
Fisher Scientific) at 4 °C for 30 min. Viruses in the allantoic fluid were
pelleted through a 20% sucrose cushion in NTE buffer (100 mM NaCl,
10 mM TrisHCl, 1 mM ethylenediaminetetraacetic acid (EDTA), pH
7.4) by centrifugation in a Beckman L765 ultracentrifuge at
25,000 rpm for 2 h at 4 °C using a Beckman SW28 rotor (Beckman
Coulter, Brea, CA, USA). Supernatants were aspirated and the pellets
were re-suspended in PBS (pH 7.4). The protein content was
determined using the bicinchoninic acid (BCA) assay (Thermo Fisher
Scientific).
2.7. Western Blot
Concentrated virus samples were mixed with NovexTM Tris-Gly-
cine SDS Sample Buffer (2X) (Thermo Fisher Scientific) with
NuPAGETM Sample Reducing Agent (10X) (Thermo Fisher Scientific).
The samples were heated at 95 °C for 5 min. Two microgram of con-
centrated viruses were resolved on 420% sodium dodecyl sulfa-
tepolyacrylamide gel electrophoresis (SDS-PAGE) gels (Biorad)
using the NovexTM Sharp Pre-stained Protein Standard (Thermo
Fisher Scientific) as the marker. Proteins were transferred onto poly-
vinylidene difluoride (PVDF) membrane (GE healthcare). The mem-
brane was blocked with 5% dry milk in PBS containing 0.1% v/v
Tween 20 (PBST) for 1 h at RT. The membrane was washed with PBST
on a shaker 3 times (10 min at RT each time) and incubated with pri-
mary antibodies diluted in PBST containing 1% BSA overnight at 4 °C.
To detect the spike protein of SARS-CoV-2, a mouse monoclonal anti-
body 2B3E5 kindly provided by Dr. Thomas Moran at ISMMS was
used, while the HN protein was detected by a mouse monoclonal
antibody 8H2 (MCA2822, Bio-Rad). The membranes were then
washed with PBST on a shaker 3 times (10 min at RT each time) and
incubated with sheep anti-mouse IgG linked with horseradish perox-
idase (HRP) diluted (1:2000) in PBST containing 5% dry milk for 1 h at
RT. The secondary antibody was discarded and the membranes were
washed with PBST on a shaker 3 times (10 min at RT each time).
PierceTM ECL Western Blotting Substrate (Thermo Fisher Scientific)
was added to the membrane, the blots were imaged using the Bio-
Rad Universal Hood Ii Molecular imager (Bio-Rad) and processed by
Image Lab Software (Bio-Rad).
2.8. Mice immunizations
Ten-week old female BALB/cJ mice (Jackson Laboratories) were
used. Experiments were performed in accordance with protocols
approved by the Icahn School of Medicine at Mount Sinai Institu-
tional Animal Care and Use Committee (IACUC). The animal experi-
ment was in compliance to the ARRIVE guidelines [26]. Mice were
divided into 9 groups (n = 5) receiving four different concentrated
live viruses at two doses (10 mg and 50 mg) intramuscularly (i.m).
Specifically, group 1 (10 mg per mouse) and 2 (50 mg per mouse)
were given wild type NDV_LS; group 3 (10 mg per mouse) and 4
(50 mg per mouse) received NDV_LS_S; group 5 (10 mg) and 6
(50 mg) received NDV_LS_S-F and group 7 (10 mg per mouse) and 8
(50 mg per mouse) received NDV_LS/L289A_S-F. Group 9 given PBS
was used as the negative controls. A prime-boost immunization regi-
men was used for all the groups in a 3-week interval.
2.9. Enzyme linked immunosorbent assay (ELISA)
Immunized mice were bled pre-boost and 8 days after the boost.
Sera were isolated by low-speed centrifugation. To perform ELISAs,
Immulon 4 HBX 96-well ELISA plates (Thermo Fisher Scientific) were
coated with 2 mg/ml of recombinant trimeric S protein (50 mL per
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[21]. The next day, all plates were washed 3 times with 220 mL PBS
containing 0.1% (v/v) Tween-20 (PBST) and 220 mL blocking solution
(3% goat serum, 0.5% dry milk, 96.5% PBST) was added to each well
and incubated for 1 h at RT. Mouse sera were 3-fold serially diluted in
blocking solution starting at 1:30 followed by a 2 h incubation at RT.
ELISA plates were washed 3 times with PBST and 50 mL of sheep
anti-mouse IgG-horseradish peroxidase (HRP) conjugated antibody
(GE Healthcare) was added at a dilution of 1:3000 in blocking solu-
tion. Then, plates were again incubated for one hour at RT. Plates
were washed 3 times with PBST and 100 mL of o-phenylenediamine
dihydrochloride (SigmaFast OPD, Sigma) substrate was added per
well. After 10 min, 50 mL of 3 M hydrochloric acid (HCl) was added to
each well to stop the reaction and the optical density (OD) was mea-
sured at 492 nm on a Synergy 4 plate reader (BioTek). An average of
OD values for blank wells plus three standard deviations was used to
set a cutoff for plate blank outliers. A cutoff value was established for
each plate that was used for calculating the endpoint titers. The end-
point titers of serum IgG responses was graphed using GraphPad
Prism 7.0.
2.10. SARS-CoV-2 challenge in mice
The SARS-CoV-2 challenge was performed at the University of
North Carolina by Dr. Ralph Baric’s group in a Biosafety Level 3 (BSL-
3) facility. Mice were challenged 11 days after the boost using a
mouse adapted SARS-CoV-2 strain at 104 plaque forming unit (PFU)
intranasally (i.n) under ketamine/xylazine anesthesia as described
previously [2,27].
2.11. Lung titers
Lung lobes of mice were collected and homogenized in PBS. A pla-
que assay was performed to measure viral titer in the lung homoge-
nates as described previously [2,27]. Geometric mean titers of plaque
forming units (PFU) per lobe were calculated using GraphPad
Prism 7.0.
2.12. Micro-neutralization assay
All neutralization assays were performed in the biosafety level 3
(BSL-3) facility following institutional guidelines as described previ-
ously [21,28]. Briefly, serum samples were heat-inactivated at 56 °C
for 60 min prior to use. 2X minimal essential medium (MEM)
supplemented with glutamine, sodium biocarbonate, 4
(2hydroxyethyl)1piperazineethanesulfonic acid (HEPES), and
antibiotics P/S was used for the assay. Vero E6 cells were maintained
in culture using DMEM supplemented with 10% fetal bovine serum
(FBS). Twenty-thousands cells per well were seeded the night
before in a 96-well cell culture plate. 1X MEM was prepared from
2X MEM and supplemented with 2% FBS. Three-fold serial dilutions
starting at 1:20 of pooled sera were prepared in a 96-well cell cul-
ture plate and each dilution was mixed with 600 times the 50% tis-
sue culture infectious dose (TCID50) of SARS-CoV-2 (USA-WA1/
2020, BEI Resources NR-52281). Serum-virus mixture was incubated
for 1 h at room temperature. Virus-serum mixture was added to the
cells for 1 h and kept in a 37 °C incubator. Next, the virus-serum
mixture was removed and the corresponding serum dilution was
added to the cells with addition 1X MEM. The cells were incubated
for 2 days and fixed with 100 mL 10% formaldehyde per well for
24 h before taken out of the BSL-3 facility. The staining of the cells
was performed in a biosafety cabinet (BSL-2). The formaldehyde
was carefully removed from the cells. Cells were washed with 200
mL PBS once before being permeabilized with PBS containing 0.1%
Triton X-100 for 15 min at RT. Cells were washed with PBS and
blocked in PBS containing 3% dry milk for 1 h at RT. Cells were thenstained with 100 mL per well of a mouse monoclonal anti-NP anti-
body (1C7), kindly provided by Dr. Thomas Moran at ISMMS, at
1 mg/ml for 1 h at RT. Cells were washed with PBS and incubated
with 100 mL per well Antimouse IgG HRP (Rockland) secondary
antibody at 1:3000 dilution in PBS containing 1% dry milk for 1 h at
RT. Finally, cells were washed twice with PBS and the plates were
developed using 100 mL of SigmaFast OPD substrate. Ten minutes
later, the reactions were stopped using 50 mL per well of 3 M HCI.
The OD 492 nM was measured on a Biotek SynergyH1 Microplate
Reader. Nonlinear regression curve fit analysis (The top and bot-
tom constraints are set at 100% and 0%) over the dilution curve was
performed to calculate 50% of inhibitory dilution (ID50) of the serum
using GraphPad Prism 7.0.
2.13. Immunohistochemistry (IHC)
The lung lobes of mice were perfused and fixed in 10% phosphate
buffered formalin for 7 days before transferred out of the BSL-3 facil-
ity. The fixed lungs were paraffin embedded, and sectioned at 5 mm
for immunohistochemistry (IHC) staining (HistoWiz). IHC was per-
formed using a rabbit SARS-CoV-2 nucleocapsid (N) protein
(NB10056,576, Novus Biologicals). Slides were counter stained with
hematoxylin. All slides were examined by a board-certified veteri-
nary pathologist (HistoWiz).
2.14. Statistics
Statistical analysis was performed using GraphPad Prism 7.0. The
statistical difference in viral titers in the lungs was determined using
one-way analysis of variance (ANOVA), and corrected for multiple
comparisons using Dunnett’s test.
2.15. Role of funding source
The funders have no role in study design, data collection, data
analyses, interpretation, or writing of report
3. Results
3.1. Design and rescue of NDV LaSota expressing the spike protein of
SARS-CoV-2
For protective immunity, the S protein is the most important anti-
gen of SARS-CoV-2. To express S antigen by the NDV LaSota vaccine
strain, we designed two constructs. One is the wild type spike (S), the
other is the spike-F chimera (S-F). The S-F consists of the ectodomain
of the S, in which the polybasic cleavage site 682RRAR685 is removed
by deleting the three arginines [21]. Importantly, to increase mem-
brane-anchoring of the spike on the surface of the NDV virions, we
replaced the transmembrane domain (TM) and cytoplasmic tail (CT)
of the spike with those from the fusion (F) protein of NDV (Fig. 1a)
[29]. The nucleotide sequences of each construct were inserted
between the P and M genes of the antigenomic cDNA of WT NDV
LaSota strain and/or NDV LaSota/L289A mutant strain, in which the
mutation L289A in the F protein supports HN independent fusion
[23]. The latter NDV mutant has been safely used in humans [15]
(Fig. 1b). NDV expressing the spike proteins were rescued by tran-
sient transfection of BSRT7 cells followed by amplification in embryo-
nated chicken eggs. All the viruses expressing the S or S-F grew to
high titers (~108 FFU/ml) in embryonated chicken eggs (Fig. 1c),
which is advantageous for the development of a low-cost vaccine.
3.2. The spike protein is incorporated into NDV particles
To validate the expression of S and S-F as transgenes, Vero E6 cells
were infected with WT NDV or NDV expressing the S or S-F. The
Fig. 1. NDV vectors expressing the spike protein of SARS-CoV-2. (a) Two forms of spike proteins expressed by NDV. Spike (S) has the wild type amino acid sequence. The Spike-F chi-
mera (S-F) consists of the ectodomain of S without the polybasic cleavage site and the transmembrane domain (TM) and cytoplasmic tail (CT) of the F protein from NDV. (b) Illustra-
tion of genome structures of wild type NDV LaSota (WT NDV_LS), NDV expressing the S or S-F in the wild type LaSota backbone (NDV_LS_S or NDV_LS_S-F) or NDV expressing the
S-F in the L289A mutant backbone (NDV_LS/L289A_S-F). The L289A mutation supports the HN-independent fusion of the F protein. (c) Titers of NDV vectors grown in embryonated
chicken eggs. The rescued viruses were grown in 10-day old embryonated chicken eggs for 2 or 3 days at 37 °C at limited dilutions. The peak titers of each virus were determined by
immunofluorescence assay (IFA). The error bars represent standard deviation (SD).
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specific monoclonal antibody CR3022 that recognizes the RBD. We
confirmed that only NDV expressing the S or S-F showed robust
expression of the spike on the cell surface, while NDV proteins were
detected in all virus-infected cells (Fig. 2a). This demonstrates that S
and S-F are successfully expressed by the NDV. To examine the incor-
poration of the S and S-F into the NDV virions, we concentrated the
NDV_LS_S, NDV_LS_S-F and NDV_LS/L289A_S-F through a 20%
sucrose cushion. The pellets were re-suspended in PBS. The WT
NDV_LS was prepared the same way and was used as the negative
control. The protein content of each concentrated virus was deter-
mined by BCA assay. Two micrograms of each virus was resolved on
an SDS-PAGE. A Western blot was performed to examine the abun-
dance of the spike using mouse monoclonal antibody 2B3E5 that
binds to a linear epitope of the S1 protein. The expression of the NDV
viral hemagglutinin-neuraminidase (HN) protein was also shown as
an internal control of the concentrated viruses (Fig. 2b). As expected,
both S and S-F incorporated into the NDV particles. Of note, the WT S
harboring the polybasic cleavage site (CS) was completely cleaved
showing only the S1, while the S-F was maintained at its uncleaved
S0 stage. Importantly, the S-F expressed either by the WT or L289A
NDV_LS backbone exhibited superior incorporation into the virions
over the WT S shown by much higher abundance of S-F than S1
cleaved from the WT S (Fig. 2b). This confirms that the TM/CT of F in
the S-F chimera indeed facilitates the membrane-anchoring of the
spike as expected. Since the anti-NDV rabbit sera completely neutral-
ize focus formation of these three NDV vectors vaccines, and for the
fact, that the S-F constructs don’t have a polybasic cleavage site, it is
unlikely the expression of the transgenes alters the tropism of these
viruses.3.3. Immunization of mice with NDV LaSota expressing the spike protein
elicited potently binding and neutralizing antibodies
To evaluate the immunogenicity of our NDV vectors expressing
the S or S-F as vaccine candidates against SARS-CoV-2, a proof of
principle study was performed in mice. Specifically, BALB/c mice
were immunized with live NDV_LS_S, NDV_LS_S-F and NDV_LS/
L289A_S-F intramuscularly, as live NDV barely replicates in the mus-
cle and causes no symptoms in mammals. Here, we used a prime-
boost immunization regimen in a three-week interval. Mice were
bled pre-boost (after prime) and 8 days after the boost for in vitro
serological assays (Fig. 3a). Two doses (10 mg and 50 mg) of each
NDV construct including NDV_LS_S (group 3 and 4), NDV_LS_S-F
(group 5 and 6) and NDV_LS/L289A_S-F (group 7 and 8) were tested
as shown in Fig. 3a. Animals vaccinated with WT NDV expressing no
transgenes (group 1 and 2) were used as vector-only controls. Mice
receiving only the PBS (group 9) were used as negative controls.
Mouse sera from the two bleedings were harvested. Serum IgG titers
and neutralizing antibody titers were measured by ELISAs and
microneutralization assays, respectively. To perform ELISA, full-
length trimeric spike protein was coated onto ELISA plates. The end-
point titers of serum IgG were used as the readout (Fig. 3b). After
one immunization, all the NDV constructs expressing the spike pro-
tein elicited S-binding antibodies, whereas WT NDV constructs and
PBS controls show negligible antibody binding signals. The second
immunization significantly increased the antibody titers around 1
week after the boost without showing significant difference among
the three NDV constructs (Fig. 3b). The neutralizing activity of the
antibodies was measured in a microneutralization assay using the
USA-WA1/2020 SARS-CoV-2 strain. Pooled sera from each group
Fig. 2. Expression of spike protein in infected cells and NDV particles. (a) Expression of the S and S-F protein in infected cells. Vero E6 cells were infected with three NDV vectors
encoding the S or S-F for 16 to 18 h. A WT NDV control was included. The next day, cells were fixed with methanol-free paraformaldehyde. Surface proteins were stained with anti-
NDV rabbit serum or a spike receptor-binding domain (RBD)-specific monoclonal antibody CR3022. A scale bar of 200 mMwere shown. (b) Incorporation of S and S-F into NDV par-
ticles. Three NDV vectors expressing the S or S-F including the NDV_LS_S (green), NDV_LS_S-F (red) and NDV_LS/L289A_S-F (blue) were concentrated through a 20% sucrose cush-
ion. Two clones were shown for NDV_LS_S and NDV_LS_S-F. The concentrated WT NDV expressing no transgenes was used as a control. Two micrograms of each concentrated virus
were resolved on a 420% SDS-PAGE, the spike protein and NDV HN protein were detected by western blot using an anti-spike 2B3E5 mouse monoclonal antibody and an anti-HN
8H2 mouse monoclonal antibody.
6 W. Sun et al. / EBioMedicine 62 (2020) 103132were tested in a technical duplicate. The ID50 value was calculated as
the readout of neutralizing activity of post-boost sera (Day 29). Sera
from all vaccinated groups showed neutralizing activity. The neutral-
ization titer of sera from the NDV_LS_S high-dose (50 mg) vaccina-
tion group (ID50  444) appeared to be slightly higher than that
from the low-dose (10 mg) vaccination group (ID50 178). No sub-
stantial difference was observed between the low-dose and high-
dose groups using the NDV_LS_S-F and NDV_LS/L289A_S-F con-
structs (Fig. 3c), the neutralization titers of which are comparable to
that of the NDV_LS_S high-dose (50mg) group. To summarize, all the
NDV vectors that were engineered to express the S or S-F elicited
high titers of binding and neutralizing antibodies in mice. The WT S
and S-F constructs appeared to exhibit similar immunogenicity
when expressed by live NDV vectors that were given intramuscu-
larly to mice.
3.4. Immunization with NDV LaSota expressing the spike proteins
protects mice from challenge with a mouse-adapted SARS-CoV-2
To assess in vivo activity of S-specific antibodies induced by the
NDV constructs as well as potential cell-mediated protection, we
took advantage of a mouse  adapted SARS-CoV-2 strain that repli-
cates efficiently in BALB/c mice [2,27]. The immunized mice were
challenged with 104 PFU of the mouse-adapted SARS-CoV-2 at day 11
after the boost, and viral titers in the lungs at day 4 post challengewere measured. Mice receiving WT NDV and PBS exhibited high viral
titers in the lung, while all the groups given NDV expressing the S or
S-F showed no detectible viral load in the lung (Fig. 4a). The lungs of
infected mice were fixed in 10% neutral buffered formalin for IHC
staining using an anti-SARS-CoV-2 NP antibody. The IHC staining
showed that the SARS-CoV-2 NP protein was largely detected in the
lungs of mice that received NDV_LS WT or PBS. The SARS-CoV-2 NP
was absent in the lungs of mice vaccinated with the three NDV con-
structs expressing the S or S-F protein (Fig. 4b). These data demon-
strated that the all three NDV vector vaccines could efficiently
prevent SARS-CoV-2 infection in a mouse model.
4. Discussion
The consequences of the ongoing COVID-19 pandemic since the
end of 2019 are disheartening. With the high transmissibility of the
culprit, SARS-CoV-2, and the lack of substantial pre-existing immu-
nity of humans to this virus, many people have succumbed to COVID-
19, especially the elderly and people with underlying health
conditions. With both therapeutic and prophylactic countermeasures
[30-32] still under rapid development, no currently available treat-
ment appears to be effective enough for an over-burdened health
care system with limited resources. A vaccine is needed to prevent or
at least attenuate the symptoms of COVID-19. As many vaccine candi-
dates are being tested in pre-clinical or clinical studies, a vaccine for
Fig. 3. NDV vector vaccines elicit high titers of binding and neutralizing antibodies in mice. (a) Vaccination groups and regimen. A prime-boost vaccination regimen was used with a
three-week interval. Mice (n = 5) were bled pre-boost and 8 days after the boost. Mice were challenged with a mouse-adapted SARS-CoV-2 MA strain 11 days after the boost. A total
of ten groups of mice were used in a vaccination and challenge study. Group 1 (10 mg) and 2 (50 mg) received the WT NDV; Group 3 (10 mg) and 4 (50 mg) received the NDV_LS_S;
Group 5 (10 mg) and 6 (50 mg) received NDV_LS_S-F; Group 7 (10 mg) and 8 (50 mg) received NDV_LS/L289A_S-F; Group 9 received PBS as negative controls. An age-matched
healthy control group 10 was provided upon challenge. (b) Spike-specific serum IgG titers measured by ELISAs. Sera from animals at 3 weeks after-prime (patterned bars) and
8 days after-boost (solid bars) were isolated. Serum IgG was measured against a recombinant trimeric spike protein by ELISAs. The endpoint titers (mean with SD) were calculated
as the readout for ELISAs. (c) Neutralization titers of serum antibodies. Sera from 3 weeks after-prime and 8 days after-boost were pooled within each group. Technical duplicates
were performed to measure neutralization activities of serum antibodies using a USA-WA1/2020 SARS-CoV-2 strain. The ID50 value was calculated as the readout of the neutraliza-
tion assay. For the samples (WT NDV and PBS groups) showing no neutralizing activity in the assay, an ID50 of 10 was given as the starting dilution of the sera is 1:20 (LoD: limit of
detection). The error bars represent SD.
W. Sun et al. / EBioMedicine 62 (2020) 103132 7cost effective production in low- and middle-income countries has
not yet been developed and is still very much in need. Also, the vacci-
nation of small numbers of high-income populations who can afford
the vaccine would not efficiently prevent the spreading of the disease
in the global population. In this report, we describe promising viral
vector vaccine candidates based on NDV expressing the major anti-
gen of SARS-CoV-2. The NDV vectors were engineered to express
either the wild type S or a polybasic cleavage site removed spike with
improved membrane anchoring (S-F). These NDV vector vaccines
showed robust growth in embryonated chicken eggs despite the fact
that a large transgene is inserted into the NDV genome. Importantly,
the spike protein is successfully expressed in infected cells, and the
S-F construct exhibited superior incorporation into NDV particles,
which could potentially be used as an inactivated virus vaccine
as well.
In a proof of principle study, mice receiving live NDV vector vac-
cines twice intramuscularly have developed high levels of spike-spe-
cific antibodies that are neutralizing. Mice given the NDV vector
expressing S or S-F were protected equally well against the challenge
of a mouse-adapted SARS-CoV-2 strain showing no detectable infec-
tious virus or viral antigens in the lungs, while high viral titers were
observed in the lungs of mice given the WT NDV expressing no trans-
genes or PBS. In this study, we did not see significant dose-dependent
antibody responses, which was similar to what was observed for dif-
ferent doses (100 mg and 250 mg) of mRNA vaccine in a human trial
[1]. It could be that we did not measure the peak antibody responses
due to the problem of having to transfer mice to the University of
North Carolina for the challenge study, or an antibody response ceilingwas reached with the low dose of 10mg concentrated virus in mice. In
the present study, cellular immunity was not measured, however, this
will be of interest to investigate in the future studies. Nevertheless,
this study strongly supports that the NDV vector vaccines are promis-
ing, as they are expressing immunogenic spike proteins of SARS-CoV-
2 inducing high levels of protective antibodies. Unlike other viral vec-
tors that humans might be exposed to, the NDV vector would deliver
the spike antigen more efficiently without encountering pre-existing
immune responses in humans. In addition to the excellent safety his-
tory of NDV vectors, the complete neutralization of NDV-vectors
expressing the SARS-CoV-2 spike protein by anti-NDV sera observed
by our group as well as other groups [33] demonstrates that the trans-
gene is unlikely to change the tropism of the virus. This further
ensures the safety of this type of vaccine in humans. Importantly,
NDV vector vaccines are not only cost-effective with respect to large
scale manufacturing but can also be produced under BSL-2 conditions
using influenza virus vaccine production technology. In summary,
NDV vector SARS-CoV-2 vaccines are a safe and immunogenic alterna-
tive to other SARS-CoV-2 vaccines that can be produced using existing
infrastructure in a cost-effective way.Contributors
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